文献速递临床免疫临床生化

B型利钠肽检测的新问题

New issues on measurement of B-type natriuretic peptides.
PubMed 文献 · Clin Chem Lab Med · 2017-01-01

本文讨论B型利钠肽(BNP)系统检测的分析局限与临床解读难点,比较活性激素BNP与非活性肽N端proBNP(NT-proBNP)的生化及病理生理差异。作者指出两者提供互补信息,临床解读需结合患者临床情境与免疫分析特性,尤其在使用血管紧张素受体-脑啡肽酶抑制剂(ARNI)的患者中。

要点

  • BNP与NT-proBNP生化及病理生理特性不同,检测与解读各有局限。
  • NT-proBNP免疫分析特性更优,但BNP提供互补的病理生理信息。
  • 使用ARNI类药物时,需结合临床情境正确解读利钠肽变化。

核心结论

  • 目前临床医生应准确考虑患者临床情境及BNP与NT-proBNP免疫分析特性,以正确解读商业实验室方法测得的利钠肽变化,尤其在使用血管紧张素受体-脑啡肽酶抑制剂治疗的患者中。

主要发现

  • 活性激素BNP的检测相比非活性肽NT-proBNP存在若干分析局限和临床解读困难,源于两肽生化与病理生理特征不同及商业免疫分析方法的质量规格差异。
  • 因NT-proBNP免疫分析特性更优且心衰患者NT-proBNP水平变化更易解读,部分作者主张测非活性肽NT-proBNP替代活性激素BNP用于心衰管理。
  • 活性肽激素BNP检测提供与非活性NT-proBNP不同但互补的病理生理和临床信息。
  • 建立更敏感特异的生物活性肽BNP1-32新检测方法应能提供关于循环利钠活性的更准确信息。

临床怎么用

  • 临床解读利钠肽变化时需结合患者临床情境与BNP/NT-proBNP免疫分析特性。
  • 使用血管紧张素受体-脑啡肽酶抑制剂治疗的患者中尤需注意利钠肽的正确解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The measurement of the active hormone of B-type natriuretic peptide (BNP) system actually has several analytical limitations and difficulties in clinical interpretations compared to that of inactive peptide N-terminal proBNP (NT-proBNP) because of the different biochemical and pathophysiological characteristics of two peptides and quality specifications of commercial immunoassay methods used for their measurement. Because of the better analytical characteristics of NT-proBNP immunoassays and the easier pathophysiological and clinical interpretations of variations of NT-proBNP levels in patients with heart failure (HF), some authors claimed to measure the inactive peptide NT-proBNP instead of the active hormone BNP for management of HF patients. The measurement of the active peptide hormone BNP gives different, but complementary, pathophysiological and clinical information compared to inactive NT-proBNP. In particular, the setup of new more sensitive and specific assays for the biologically active peptide BNP1-32 should give better accurate information on circulating natriuretic activity. In conclusion, at present time, clinicians should accurately consider both the clinical setting of patients and the analytical characteristics of BNP and NT-proBNP immunoassays in order to correctly interpret the variations of natriuretic peptides measured by commercially available laboratory methods, especially in patients treated with the new drug class of angiotensin receptor-neprilysin inhibitors.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Clerico A, Zaninotto M, Passino C, et al. New issues on measurement of B-type natriuretic peptides. Clin Chem Lab Med. 2017. PMID: 28809748. doi:10.1515/cclm-2017-0433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。